ARTICLE | Translation in Brief
The bystander effect of Treg depletion
Why modality could be critical for Treg-targeted therapies
November 15, 2018 10:33 PM UTC
Limiting bystander effects of immunosuppressive Treg-targeting therapies may be crucial for their antitumor efficacy, according to data released last week at the Society for Immunotherapy of Cancer meeting.
Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) presented Phase I and Phase I/II data on Nov. 9 showing that while Poteligeo mogamulizumab, an anti-CC chemokine receptor 4 (CCR4; CD194) mAb, depleted Tregs in the periphery and tumor stroma, the depletion did not correlate with efficacy...
BCIQ Target Profiles